Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12635865 | 0.88 | KLK5 (0.52) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL17993808 | 0.85 | KLK5 (0.47) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14947691 | 0.85 | MEN1 (0.38) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL15108314 | 0.83 | KLK5 (0.45) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6446258 | 0.82 | KLK5 (0.50) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13246042 | 0.81 | KLK5 (0.43) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9848360 | 0.77 | KLK5 (0.63) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7270592 | 0.77 | KLK5 (0.63) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6444857 | 0.77 | KLK5 (0.63) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6445261 | 0.77 | KLK5 (0.63) | KLK5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148374-B2 | Concurrent administering of drugs; side effect reduction | GILEAD SCIENCES, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8088770-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES,INC. (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181902-A1 | Modulators of pharmacokinetic properties of therapeutics | SLC10A1, SLC10A2, SLC26A4 | KLK5 679/4885PSEN1 3006/4885PSEN2 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.